Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 876

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 876
---
 Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, may be permitted to directors, officers and controlling persons of the Company, the Company has been advised that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. II-1

Item 21.Exhibits And Financial Statements Schedules (a) Exhibits The following exhibits are filed as part of this Registration Statement:

| Exhibit 
 Number  
 2.1     
 2.2     |     | Description of Document                                                                                                                                                                                                                                                       
 Agreement and Plan of Merger, dated as of November 4, 2024, by and among NLS Pharmaceutics Ltd., NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd. (included as Annex A to the proxy statement/prospectus forming a part of this Registration Statement)                    
 Amendment No. 1 to Agreement and Plan of Merger, dated as of January 30, 2025, by and among NLS Pharmaceutics Ltd., NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd. (included in Annex A to the proxy statement/prospectus forming a part of this Registration Statement) |
|:--------|:----|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2.3     |     | Amendment No. 2 to Agreement and Plan of Merger, dated as of February 4, 2025, by and among NLS Pharmaceutics Ltd., NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd. (included in Annex A to the proxy statement/prospectus forming a part of this Registration Statement) |
| 3.1     |     | Amended and Restated Articles of Association of NLS Pharmaceutics Ltd. (filed as Exhibit 99.1 to Form 6-K (File No. 001-39957) filed on November 15, 2024).                                                                                                                   |
| 3.2     |     | Form of Amended and Restated Articles of Association of NLS Pharmaceutics Ltd. (included as Annex D to the proxy statement/prospectus forming a part of this Registration Statement)                                                                                          |
| 4.1     |     | Form of Pre-funded Warrant                                                                                                                                                                                                                                                    |
| 4.2     |     | Form of